"Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?"

Joint Bone Spine

Volumn 78, Issue 4, 2011, Pages 331-334

  Fiocco, Ugo ^a   Punzi, Leonardo ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti TNF alpha; Intra articular therapy; Peripheral spondyloarthropathies; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; PLACEBO; SHORT HAIRPIN RNA; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHRITIS; CORTICOSTEROID THERAPY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; EDITORIAL; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PIGMENTED VILLONODULAR SYNOVITIS; PSORIATIC ARTHRITIS; REPEATED DRUG DOSE; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SINGLE DRUG DOSE; SPONDYLOARTHROPATHY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; HUMANS; INJECTIONS, INTRA-ARTICULAR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960633770     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.01.005     Document Type: Editorial

References (38)

1. Fisher B.A., Keat A. Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis?. J Rheumatol 2006, 33:1934-1935.
2. Garrood T., Pitzalis C. Targeting the inflamed synovium: the quest for specificity. Arthritis Rheum 2006, 54:1055-1060.
3. Bliddal H., Terslev L., Qvistgaard E., et al. A randomized, controlled study of a single intraarticular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 2006, 35:341-345.
4. van der Bijl A.E., Teng Y.K., van Oosterhout M., et al. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial. Arthritis Rheum 2009, 61:974-978.
5. Tracey D., Klareskog L., Sasso E.H., et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
6. Conti F., Ceccarelli F., Priori R., et al. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha. Ann Rheum Dis 2008, 67:1787-1790.
7. Boesen M., Boesen L., Jensen K.E., et al. Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. J Rheumatol 2008, 35:584-589.
8. Nikas S.N., Temekonidis T.I., Zikou A.K., et al. Treatment of resistant rheumatoid arthritis by intraarticular infliximab injections: a pilot study. Ann Rheum Dis. 2004, 63:102-103.
9. Kobak S. Osteonecrosis and monoarticular rheumatoid arthritis treated with intra-articular adalimumab. Mod Rheumatol 2008, 18:290-292.
10. Alstergren P., Larsson P.T., Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. Scand J Rheumatol 2008, 37:155-157.
11. Bello S., Bonali C., Serafino L., et al. Intra-articular therapy with infliximab in psoriatic arthritis: efficacy and safety in refractory monoarthritis. Reumatismo 2010, 62:46-50.
12. Fiocco U., Sfriso P., Nardacchione R., et al. Evaluation of the efficacy and safety of repeated intra-articular etanercept injections in resistant knee joint synovitis. Arthritis Rheum 2007, 56:S592.
13. Fiocco U., Ferro F., Vezzu M., et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005, 64:899-905.
14. Cañete J.D., Pablos J.L., Sanmartí R., et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004, 50:1636-1641.
15. Kruithof E., De Rycke L., Roth J., et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies. Arthritis Rheum 2005, 52:3898-3909.
16. van Kuijk A.W., Gerlag D.M., Vos K., et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 2009, 68:1303-1309.
17. Ahern M.J., Campbell D.G., Weedon H., et al. The effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy. Ann Rheum Dis 2008, 67:1339-1342.
18. McGonagle D., Lories R.J., Tan A.L., Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007, 56:2482-24891.
19. Fiocco U., Cozzi L., Chieco-Bianchi F., et al. Vascular changes in psoriatic knee joint synovitis. J Rheumatol 2001, 28:2480-2486.
20. Fiocco U., Sfriso P., Oliviero F., et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-alpha blockade in the knee joint. Arthritis Res Ther 2010, 12:R148.
21. Fiocco U., Sfriso P., Scagliori E., et al. Soft tissue changes induced by repeated serial intra-articular etanercept injections in the knee joints of patients with resistant knee joint synovitis. Arthritis Rheum 2008, 58:S588.
22. Izquierdo E., Cañete J.D., Celis R., et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One 2009, 4:e8131.
23. Fiocco U., Sfriso P., Lunardi F., et al. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis. Autoimmun Rev 2010, 9:780-784.
24. Ashraf S., Mapp P.I., Walsh D.A. Angiogenesis and the Persistence of Inflammation in a rat model of proliferative synovitis. Arthritis Rheum 2010, 62:1890-1898.
25. af Klint E., Grundtman C., Engström M., et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum 2005, 52:3880-3889.
26. Ng C.T., Biniecka M., Kennedy A., et al. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis 2010, 69:1389-1395.
27. Badot V., Galant C., Nzeusseu T.A., et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R57.
28. Ritchlin C.T., Haas-Smith S.A., Li P., et al. Mechanisms of TNF-alpha and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831.
29. Vandooren B., Cantaert T., Noordenbos T., et al. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008, 58:718-729.
30. Lories R.J., Derese I., Luyten F.P., et al. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008, 26:96-102.
31. Chiu Y.G., Shao T., Feng C., et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010, 12:R14.
32. Eder L., Chandran V., Schentag C.T., et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology 2010, 49:1361-1366.
33. Eder L., Chandran V., Ueng J., et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 2010, 49:1367-1373.
34. Chatzigiannis I., Kakavouli G., Sakellariou G., et al. Intra-articular injection of infliximab in resistant inflamed joints of rheumatoid arthritis and spondyloarthropathies. Ann Rheum Dis 2004, 63:418.
35. Mease P.J., Wei N., Fudman E.J., et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol 2010, 37:692-703.
36. Evans C. Arthritis gene therapy trials reach phase II. J Rheumatol 2010, 37:683-685.
37. Khoury M., Courties G., Fabre S., et al. Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. Arthritis Rheum 2010, 62:765-770.
38. Boissier MC. Cell and cytokines imbalances in rheumatoid arthritis. Joint Bone Spine doi:10.1016/j.jbspin.2010.08.017.